Omicron

Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine

Retrieved on: 
Thursday, August 18, 2022 - 1:00pm

In Figure B, three additional participants with suspected asymptomatic seroconversion were removed from the day 181 analysis (n=6, day 181).

Key Points: 
  • In Figure B, three additional participants with suspected asymptomatic seroconversion were removed from the day 181 analysis (n=6, day 181).
  • Neutralizing antibody responses against Omicron variants BA.1, BA.2, and BA.5 were measured at the Moore Lab in South Africa.
  • These data show sustained neutralizing responses to antigenically distinct variants of concern, including Omicron BA.5, for at least six months after vaccination.
  • The Arcturus logo and other trademarks of Arcturus appearing in this announcement, including LUNAR and STARR, are the property of Arcturus.

WeTrade Group Inc. Ready to kick-off a Strategic Partnership with Zhixun Bio through WeTrade's SaaS platform and its the Internet of Things (IoT)

Retrieved on: 
Thursday, August 18, 2022 - 1:23pm

WeTrade and Zhixun are ready to launch an in-depth cooperative sales promotion of Zhixun's disinfectant - Zhuchang in China and international markets, leveraging on WeTrade's SaaS platform and its the Internet of Things (IoT) supply chain via government entities, hospitals, malls, and other medical distribution channels.

Key Points: 
  • WeTrade and Zhixun are ready to launch an in-depth cooperative sales promotion of Zhixun's disinfectant - Zhuchang in China and international markets, leveraging on WeTrade's SaaS platform and its the Internet of Things (IoT) supply chain via government entities, hospitals, malls, and other medical distribution channels.
  • Zhuchang disinfectant has passed three prevailing testing authorities in China, i.e.
  • Hubei Center for Disease Control, Guangzhou Customs Technical Center and Zhongguancun International Pharmaceutical Inspection and Certification Institution.
  • This product has now completed the health and safety evaluation with PRC government, with complete approval for sales.

DGAP-News: CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate

Retrieved on: 
Thursday, August 18, 2022 - 12:07pm

CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate

Key Points: 
  • CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate
    The issuer is solely responsible for the content of this announcement.
  • The CV0501 study follows the start of a Phase 1 study in March 2022 that evaluates an unmodified second-generation COVID-19 vaccine candidate CV2CoV, encoding for the original virus variant.
  • The comprehensive approach to evaluate both an unmodified and a modified, second-generation vaccine candidate against COVID-19 is expected to identify the best-performing candidate for later-stage clinical development.
  • CV0501 is CureVacs first COVID-19 vaccine candidate applying chemically modified mRNA from the COVID-19 vaccine program developed in collaboration with GSK.

DGAP-News: CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update

Retrieved on: 
Thursday, August 18, 2022 - 12:07pm

In the second quarter of 2022, the wind-down costs related to our first-generation vaccine candidate, CVnCoV, still impacted our financial position but continue to decrease as we conclude our remaining commitments, said Pierre Kemula, Chief Financial Officer of CureVac.

Key Points: 
  • In the second quarter of 2022, the wind-down costs related to our first-generation vaccine candidate, CVnCoV, still impacted our financial position but continue to decrease as we conclude our remaining commitments, said Pierre Kemula, Chief Financial Officer of CureVac.
  • Moving into the second half of 2022, we are further broadening our mRNA technology platform and advancing our programs in prophylactic vaccines as well as executing on our core strategy in oncology.
  • CureVac is delivering on its previously announced 2022 clinical development program in prophylactic vaccines by initiating a Phase 1 study with the modified COVID-19 mRNA vaccine candidate CV0501.
  • In the first quarter of 2022, CureVac received a 10 million milestone payment related to the start of the seasonal influenza clinical trial.

Preparing for Continuing Battle with COVID, MicroGEM Partners with Medline to Equip Healthcare Providers with World's First Saliva PCR Test for Point of Care

Retrieved on: 
Wednesday, August 17, 2022 - 7:10pm

CHARLOTTESVILLE, Va., Aug. 17, 2022 /PRNewswire/ -- MicroGEM, a U.S.-based molecular biology company, today announced that Medline, a manufacturer and distributor of medical supplies to healthcare providers across the continuum of care, is now offering the MicroGEM Sal6830 Point of Care PCR System and SARS-CoV-2 Saliva Test.

Key Points: 
  • "Our partnership with MicroGEM expands our product portfolio to offer a saliva-based test for the first time.
  • Medline is a healthcare company; a manufacturer, distributor, and solutions provider focused on improving the overall operating performance of healthcare.
  • Partnering with healthcare systems and facilities across the continuum of care, Medline provides the clinical and supply chain resources required for long-term financial viability in delivering high-quality care.
  • Headquartered in Northfield, Ill., Medline has 30,000+ employees worldwide and does business in more than 125 countries and territories.

PSYC Appoints COO for Wholly Owned Subsidiary, Spotlight Media Corp.

Retrieved on: 
Wednesday, August 17, 2022 - 1:30pm

We are truly fortunate to officially welcome such a talented, experienced, and passionate force into the PSYC family, said PSYC CEO, David Flores.

Key Points: 
  • We are truly fortunate to officially welcome such a talented, experienced, and passionate force into the PSYC family, said PSYC CEO, David Flores.
  • "Spotlight Media is boldly branching into adjacent markets to psychedelics and cannabis and understands the surprising lack of unique and meaningful media coverage in the booming wellness sector, said SMC COO, Sacha Hebbert.
  • With a balanced approach to managing talent and spearheading our future media endeavors, I seek to make Spotlight Media a relevant culture driver in the psychedelic, cannabis, and disruptive healing modality marketplaces.
  • Spotlight Media Corporation (SMC) ( www.spotlightmediacorp.com ) is a Nevada Corporation and is a privately held wholly owned subsidiary of PSYC that was incorporated on February 8, 2022.

Golden Sun Education Group Limited Reports First Half of Fiscal Year 2022 Financial Results

Retrieved on: 
Tuesday, August 16, 2022 - 9:15pm

The decrease was mainly due to less general and administrative expenses as compared to the same period of fiscal year 2021.

Key Points: 
  • The decrease was mainly due to less general and administrative expenses as compared to the same period of fiscal year 2021.
  • As a percentage of revenues, general and administrative expenses represented approximately 28% and 31% of revenues in the six months ended March 31, 2022 and 2021, respectively.
  • Net income from discontinued operationswas $nil and approximately $0.6 million in the six months ended March 31, 2022 and 2021, respectively.
  • Net income was approximately $0.4 million and $1.6 million in the six months ended March 31, 2022 and 2021, respectively.

University of Adelaide Begins Human Trial of Omicron COVID Vaccine Booster Using PharmaJet Needle-free System

Retrieved on: 
Tuesday, August 16, 2022 - 4:05pm

PharmaJet , a company that has developed and commercialized a needle-free platform to more effectively administer drugs and biologics announced that its partner, University of Adelaide, has started a human trial of a DNA-based COVID-19 vaccine booster using the PharmaJet Tropis Needle-free Injection System (NFIS).

Key Points: 
  • PharmaJet , a company that has developed and commercialized a needle-free platform to more effectively administer drugs and biologics announced that its partner, University of Adelaide, has started a human trial of a DNA-based COVID-19 vaccine booster using the PharmaJet Tropis Needle-free Injection System (NFIS).
  • The DNA-vaccine booster is one of the few vaccines worldwide targeting the Omicron variant, rather than the original strain of the virus.
  • As DNA vaccines can be modified easily the vaccine can be quickly adapted to future variants.
  • Our partners have published 11 studies comparing delivery methods for DNA vaccines that demonstrate increased immunogenicity when using the PharmaJet Systems.

PSYC Enters MOU to Acquire Technical420, LLC for $2.25M in Accretive Transaction

Retrieved on: 
Tuesday, August 16, 2022 - 1:30pm

Over the next quarter, SMC plans to accomplish the following initiatives:

Key Points: 
  • Over the next quarter, SMC plans to accomplish the following initiatives:
    Management expects the acquisition to be immediately accretive for PSYC.
  • The weakness in these sectors and the attention on the blockchain space created a recipe for declining interest from the market.
  • Looking at Spotlight Medias performance, the brand not only retained its audience but significantly increased its reach.
  • Im very excited to be joining a team of executives with a proven track record in highly regulated industries.

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Retrieved on: 
Tuesday, August 16, 2022 - 11:00am

The proposed new primary efficacy endpoints may include the time to resolution from COVID-19 via the polymerase chain reaction (PCR) test and the rate of sustained clinical resolution of certain symptoms of COVID-19.

Key Points: 
  • The proposed new primary efficacy endpoints may include the time to resolution from COVID-19 via the polymerase chain reaction (PCR) test and the rate of sustained clinical resolution of certain symptoms of COVID-19.
  • These proposed endpoints address the shift in COVID-19 clinical outcomes observed over the course of the pandemic, and, therefore, have more meaningful study endpoints for the FDA to consider for regulatory approval.
  • Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19.
  • With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders.